Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of JNJ-61393215 in healthy Japanese men
jRCT2071200091Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing JNJ-61393215 single ascending dose with Placebo (2 arms). Primary endpoints: Number of participants with adverse events (AEs) and Plasma concentration of JNJ-61393215. Started Feb 2021; status: completed.
02
Drugs
rocavorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2071200091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200091.